Hello, everyone. Thank you, again, for all of your interest in this topic. You can start to see why this has continued to capture my passion, hold my dedication, and inspire all of my "after hours" work since I began development of this technique over five years ago. The questions and concerns that many of you raised are good ones and issues that I and the increasing members of my team at Pilofocus have continued to address and optimize prior to the official disclosure of our product.
A primary maxim in medicine, Primum non nocere, or "First, do no harm," drives every decision as we bring the pilosocpe from bench to bedside. Advancing the development of this project carefully over the many years has helped ensure that our device and the novel approach used are both safe and effective when made available. Earning approval from both the Investigational Review Board (IRB) before we performed the clinical trials and the Food & Drug Administration (FDA) before making this available to all patients are essential steps that are not to be compromised.
I would also like to thank the numerous patients of mine for their respectful discretion over the months and years. Even after learning all of the exciting details and witnessing the evolving functionality of our novel technique (which eclipse any formal patent), those patients who came in for an in-depth discussion with me remained, and continue to remain, respectfully discrete (whether they opted for FUT, FUE, or to participate in the next clinical trial). I do look forward to sharing the full details with the community. Therefore, I applied for a formal presentation to my fellow physicians at this October's ISHRS Conference in San Francisco, CA. Hope to meet a few of you there!
A primary maxim in medicine, Primum non nocere, or "First, do no harm," drives every decision as we bring the pilosocpe from bench to bedside. Advancing the development of this project carefully over the many years has helped ensure that our device and the novel approach used are both safe and effective when made available. Earning approval from both the Investigational Review Board (IRB) before we performed the clinical trials and the Food & Drug Administration (FDA) before making this available to all patients are essential steps that are not to be compromised.
I would also like to thank the numerous patients of mine for their respectful discretion over the months and years. Even after learning all of the exciting details and witnessing the evolving functionality of our novel technique (which eclipse any formal patent), those patients who came in for an in-depth discussion with me remained, and continue to remain, respectfully discrete (whether they opted for FUT, FUE, or to participate in the next clinical trial). I do look forward to sharing the full details with the community. Therefore, I applied for a formal presentation to my fellow physicians at this October's ISHRS Conference in San Francisco, CA. Hope to meet a few of you there!
Comment